NCT00895245: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy |
|
|
| Terminated | 2 | 6 | US | fosaprepitant dimeglumine, cisplatin, CACP, CDDP, CPDD, DDP, Neoplatin, palonosetron hydrochloride, Aloxi, RS 25259-197, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, Decaspray, DM, DXM, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy, 3-D conformal radiotherapy or IMRT | University of Washington, National Cancer Institute (NCI) | Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx | 09/10 | 02/11 | | |
NCT01405924: Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) |
|
|
| Terminated | 2 | 111 | NA | Fosaprepitant dimeglumine, MK-0517, EMEND® IV, 5-HT3 RA, Dexamethasone, Rescue medication | Merck Sharp & Dohme LLC | Nausea, Vomiting | 12/13 | 12/13 | | |
NCT01031953: Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy |
|
|
| Terminated | 1/2 | 34 | US | fosaprepitant dimeglumine, systemic chemotherapy, survey administration, quality-of-life assessment | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | 02/13 | 02/13 | | |
